At least two initial public offerings were withdrawn during Tuesday’s brutal stock market rout, casting a shadow over what’s expected to be the year’s biggest deal, the $1.8 billon offering from AIG’s life insurer Corebridge Financial Inc.
Israel tech-focused special-purpose acquisition corporation Keter1 Acquisition withdrew its plans for an $250 million IPO on Tuesday, according to Renaissance Capital, a provider of pre-IPO institutional research and IPO-focused ETFs.
And cancer-focused biotech Elicio Therapeutics pulled its $40 million offering, according to Renaissance.
The decisions came as the Dow Jones Industrial Average
shed 1,300 points Tuesday to mark its worst one-day performance since June 11 of 2020, following an unexpectedly hot consumer-price inflation reading for August.
The S&P 500 shed 4.3%, while the Nasdaq Composite
fell 5.2% in a broad-based selloff. All 11 S&P 500 sectors finished in the red after the August consumer-price index, or CPI, rose 0.1% in August. Though the year-over-year rate slowed to 8.3% from 8.5% in July, economists had been looking for a monthly fall of 0.1% that would bring the year-over-year rate down to 8%.
Corebridge is still expected to price its deal later Wednesday, according to IPOScoop.com, although there are concerns it may come at the low end of its range of $21 to $24 a share. Corebridge is planning to offer 80 million shares to raise the most of any deal in this year’s frozen market.
In a sign of just how thin the market has been, the deal, if completed as planned, would account for more than a quarter of this year’s overall proceeds.
To be sure, Corebridge has some points in its favor, not least being that it’s profitable and has delivered solid growth. Corebridge had net income of $6.4 billion in the first half of the year on revenue of $16 billion, according to its filing documents. That was up from net income of $2.8 billion in the year-earlier period, on revenue of $11.02 billion.
The company is planning to pay quarterly dividends, offering a 4.1% annualized yield at the midpoint of its range, according to Renaissance co-Founder and CEO Bill Smith. It had $358 billion in client assets as of June 30.
The deal has a strong roster of underwriters at 43 banks, with JPMorgan acting as lead.
which operates Pennsylvania-based The Gratz Bank, priced its public offering on Tuesday at $7.50 a share, below its price range of $8.00 to $9.50. That offering was an uplisting to the Nasdaq from the OTC market. The stock was up 2.4% in recent trades.
Also on the docket Wednesday is biotech Third Harmonic Bio. THRD The company specializes in treatments for allergic and inflammatory diseases and plans to offer 9 million shares priced at $16 to $18 each.